menu
    • menu

    Company profile for Callio Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Callio Therapeutics is advancing next-generation, multi-payload antibody-drug conjugates (ADCs) with innovative payload and linker technologies. Our approach enables the targeted delivery of drug combinations to tumor cells, maximizing therapeutic benefit for cancer patients. With a focus on precision oncology, our lead program is a dual-payload HER2-targeted ADC designed to enhance efficacy and overcome resistance. Committed ...
    Callio Therapeutics is advancing next-generation, multi-payload antibody-drug conjugates (ADCs) with innovative payload and linker technologies. Our approach enables the targeted delivery of drug combinations to tumor cells, maximizing therapeutic benefit for cancer patients. With a focus on precision oncology, our lead program is a dual-payload HER2-targeted ADC designed to enhance efficacy and overcome resistance. Committed to innovation, we strive to develop transformative cancer therapies that improve patient outcomes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Callio TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Regions Greater Seattle Area, West Coast
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://calliotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/calliotx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Callio Therapeutics to Present CLIO-8221 Poster at AACR 2026
    Callio Therapeutics to Present CLIO-8221 Poster at AACR 2026

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274377/0/en/Callio-Therapeutics-to-Present-Poster-on-CLIO-8221-a-Novel-Dual-Payload-Antibody-Drug-Conjugate-at-AACR-2026.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    Callio Doses 1st Patient in Ph I of Dual-Payload ADC CLIO-8221
    Callio Doses 1st Patient in Ph I of Dual-Payload ADC CLIO-8221

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261154/0/en/Callio-Therapeutics-Doses-First-Patient-in-Phase-I-Clinical-Trial-of-Dual-Payload-ADC-CLIO-8221-in-Advanced-HER2-Expressing-Solid-Tumors.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    Callio Therapeutics Launches with $187M Series A
    Callio Therapeutics Launches with $187M Series A

    27 Feb 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/callio-therapeutics-launches-with-187m-series-a/

    CONTRACTPHARMA
    27 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search